-
Rani Therapeutics (RANI) Files $200M Mixed Shelf
-
Rani Therapeutics Holdings, Inc. (RANI) Tops Q2 EPS by 11c
-
Rani Therapeutics prices $3 million registered direct offering at $0.40 per share
-
Rani Therapeutics (RANI) Announces Research Agreement with Chugai
-
Rani Therapeutics Holdsing s (RANI) PT Lowered to $4 at Oppenheimer
-
Rani Therapeutics Holdings, Inc. (RANI) Tops Q1 EPS by 2c
-
Stifel Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)
-
BTIG Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)
-
Rani Therapeutics Holdings, Inc. (RANI) Misses Q4 EPS by 1c
-
Stifel Reiterates Buy Rating on Rani Therapeutics Holdsing (RANI)
-
Rani Therapeutics (RANI) Announces Preclinical Data Demonstrating Bioequivalence of RT-114
-
BTIG Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)
-
Rani Therapeutics (RANI) Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
-
Rani Therapeutics Holdings, Inc. (RANI) Tops Q3 EPS by 5c
-
H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)
-
Rani Therapeutics (RANI) Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
-
Rani Therapeutics (RANI) Prices $10M Share and Warrant Offering at $3/sh, Cancels Certain Existing Warrants
-
Rani Therapeutics Holdsing s (RANI) PT Lowered to $9 at H.C. Wainwright
-
Rani Therapeutics (RANI) Prices 2.8M Share Offering at $3.08/sh Registered Direct Offering
-
Stifel Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)
-
Rani Therapeutics Announces (RANI) Partnership with ProGen on Development of Oral Obesity Treatment

